These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 37994660)

  • 1. Rational design of polymer-based particulate vaccine adjuvants.
    Huete-Carrasco J; Lynch RI; Ward RW; Lavelle EC
    Eur J Immunol; 2024 Feb; 54(2):e2350512. PubMed ID: 37994660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine adjuvants to engage the cross-presentation pathway.
    Lee W; Suresh M
    Front Immunol; 2022; 13():940047. PubMed ID: 35979365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational Design of T-Cell- and B-Cell-Based Therapeutic Cancer Vaccines.
    Li WH; Su JY; Li YM
    Acc Chem Res; 2022 Sep; 55(18):2660-2671. PubMed ID: 36048514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine adjuvants: Tailoring innate recognition to send the right message.
    Lavelle EC; McEntee CP
    Immunity; 2024 Apr; 57(4):772-789. PubMed ID: 38599170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unmet needs in modern vaccinology: adjuvants to improve the immune response.
    Leroux-Roels G
    Vaccine; 2010 Aug; 28 Suppl 3():C25-36. PubMed ID: 20713254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines.
    Ceglia V; Zurawski S; Montes M; Kroll M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
    Front Immunol; 2021; 12():786144. PubMed ID: 35095862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances of vaccine adjuvants for infectious diseases.
    Lee S; Nguyen MT
    Immune Netw; 2015 Apr; 15(2):51-7. PubMed ID: 25922593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in self-adjuvanting glycoconjugate vaccines.
    Manabe Y; Chang TC; Fukase K
    Drug Discov Today Technol; 2020 Dec; 37():61-71. PubMed ID: 34895656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modes of Action for Mucosal Vaccine Adjuvants.
    Aoshi T
    Viral Immunol; 2017; 30(6):463-470. PubMed ID: 28436755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.
    Khalil SM; Tonkin DR; Snead AT; Parks GD; Johnston RE; White LJ
    J Virol; 2014 Aug; 88(16):9182-96. PubMed ID: 24899195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Vaccine adjuvant].
    Aoshi T; Ishii KJ
    Nihon Rinsho; 2011 Sep; 69(9):1547-53. PubMed ID: 21922751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological Principles Guiding the Rational Design of Particles for Vaccine Delivery.
    Gause KT; Wheatley AK; Cui J; Yan Y; Kent SJ; Caruso F
    ACS Nano; 2017 Jan; 11(1):54-68. PubMed ID: 28075558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. License to kill: Formulation requirements for optimal priming of CD8(+) CTL responses with particulate vaccine delivery systems.
    Foged C; Hansen J; Agger EM
    Eur J Pharm Sci; 2012 Mar; 45(4):482-91. PubMed ID: 21888971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection of adjuvants for vaccines targeting specific pathogens.
    Sarkar I; Garg R; van Drunen Littel-van den Hurk S
    Expert Rev Vaccines; 2019 May; 18(5):505-521. PubMed ID: 31009255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two different PEGylation strategies for the liposomal adjuvant CAF09: Towards induction of CTL responses upon subcutaneous vaccine administration.
    Schmidt ST; Olsen CL; Franzyk H; Wørzner K; Korsholm KS; Rades T; Andersen P; Foged C; Christensen D
    Eur J Pharm Biopharm; 2019 Jul; 140():29-39. PubMed ID: 31055066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiating humoral and cellular immunity using a novel hybrid polymer-lipid nanoparticle adjuvant for HBsAg-VLP vaccine.
    Liu X; Min Q; Song H; Yue A; Li Q; Zhou Q; Han W
    J Nanobiotechnology; 2023 Nov; 21(1):441. PubMed ID: 37993870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine adjuvants: putting innate immunity to work.
    Coffman RL; Sher A; Seder RA
    Immunity; 2010 Oct; 33(4):492-503. PubMed ID: 21029960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in aluminum hydroxide-based adjuvant research and its mechanism.
    He P; Zou Y; Hu Z
    Hum Vaccin Immunother; 2015; 11(2):477-88. PubMed ID: 25692535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models.
    Su J; Brunner L; Ates Oz E; Sacherl J; Frank G; Kerth HA; Thiele F; Wiegand M; Mogler C; Aguilar JC; Knolle PA; Collin N; Kosinska AD; Protzer U
    J Hepatol; 2023 Apr; 78(4):717-730. PubMed ID: 36634821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine adjuvants: mechanisms and platforms.
    Zhao T; Cai Y; Jiang Y; He X; Wei Y; Yu Y; Tian X
    Signal Transduct Target Ther; 2023 Jul; 8(1):283. PubMed ID: 37468460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.